Tomáš Papajík

1.3k total citations
109 papers, 792 citations indexed

About

Tomáš Papajík is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Tomáš Papajík has authored 109 papers receiving a total of 792 indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Pathology and Forensic Medicine, 53 papers in Genetics and 33 papers in Oncology. Recurrent topics in Tomáš Papajík's work include Lymphoma Diagnosis and Treatment (55 papers), Chronic Lymphocytic Leukemia Research (50 papers) and Viral-associated cancers and disorders (14 papers). Tomáš Papajík is often cited by papers focused on Lymphoma Diagnosis and Treatment (55 papers), Chronic Lymphocytic Leukemia Research (50 papers) and Viral-associated cancers and disorders (14 papers). Tomáš Papajík collaborates with scholars based in Czechia, Armenia and United States. Tomáš Papajík's co-authors include Eva Kriegová, Vít Procházka, Karel Indrák, Anna Petráčková, Marie Jarošová, Luděk Raida, Lenka Sedlaříková, Edgar Faber, Miloš Kudělka and Zuzana Mikulková and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Tomáš Papajík

101 papers receiving 774 citations

Peers

Tomáš Papajík

PFM

GENET

ONCOL

IMMUN

Niki Stavroyianni Greece

Stephan Schwarz Germany

Keitaro Tsushita Japan

Dipti Talaulikar Australia

Jun Takizawa Japan

Jens Krugmann Austria

Adam M. Petrich United States

Giuseppina Massini Italy

José R. Valbuena United States

Roberta Riboni Italy

Niki Stavroyianni Greece

Tomáš Papajík

335 ×0.9

PFM

448 ×1.4

GENET

222 ×0.8

ONCOL

298 ×1.4

IMMUN

192 ×1.2

Citations per year, relative to Tomáš Papajík Tomáš Papajík (= 1×) peers Niki Stavroyianni

Countries citing papers authored by Tomáš Papajík

Since Specialization

Citations

This map shows the geographic impact of Tomáš Papajík's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomáš Papajík with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomáš Papajík more than expected).

Fields of papers citing papers by Tomáš Papajík

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomáš Papajík. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomáš Papajík. The network helps show where Tomáš Papajík may publish in the future.

Co-authorship network of co-authors of Tomáš Papajík

This figure shows the co-authorship network connecting the top 25 collaborators of Tomáš Papajík. A scholar is included among the top collaborators of Tomáš Papajík based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomáš Papajík. Tomáš Papajík is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Petráčková, Anna, et al.. (2025). Rare germline ATM variants predispose to secondary cancer in chronic lymphocytic leukaemia patients. Cancer Communications. 45(6). 669–672.

Divoký, Vladimír, et al.. (2023). Deep Molecular Response Achieved with Chemotherapy, Dasatinib and Interferon α in Patients with Lymphoid Blast Crisis of Chronic Myeloid Leukaemia. International Journal of Molecular Sciences. 24(3). 2050–2050.

Čerňan, Martin, Tomáš Szotkowski, Milan Kolář, et al.. (2022). Infectious complications of induction treatment for acute myeloid leukaemia using the "7 + 3" protocol without antibiotic prophylaxis - 15 years of experience of one clinical site. Biomedical Papers. 167(3). 236–245. 1 indexed citations

Raida, Luděk, František Mrázek, Eva Kriegová, et al.. (2020). NFKB1 gene single-nucleotide polymorphisms: implications for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Annals of Hematology. 99(3). 609–618. 5 indexed citations

Manukyan, Gayane, et al.. (2020). High CXCR3 on Leukemic Cells Distinguishes IgHV ^mut from IgHV ^unmut in Chronic Lymphocytic Leukemia: Evidence from CD5 ^high and CD5 ^low Clones. Journal of Immunology Research. 2020(1). 7084268–7084268. 6 indexed citations

Petráčková, Anna, et al.. (2019). Standardization of Sequencing Coverage Depth in NGS: Recommendation for Detection of Clonal and Subclonal Mutations in Cancer Diagnostics. Frontiers in Oncology. 9. 851–851. 82 indexed citations

Manukyan, Gayane, et al.. (2018). Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia. Leukemia Research. 72. 113–119. 9 indexed citations

Raida, Luděk, Tomáš Szotkowski, Peter Rohoň, et al.. (2018). Granulocyte transfusions collected after steroid priming for severe infections during neutropenia: A single center experience. Transfusion Clinique et Biologique. 26(4). 299–303.

Kudělka, Miloš, et al.. (2017). Gender, Age and TP53 Aberrations in Context of Complex Karyotypes in Chronic Lymphocytic Leukemia Patients in the Era of Chemo +/- Immunotherapy. Blood. 130. 2991. 1 indexed citations

10.

Procházka, Vít, et al.. (2015). Numbers of CD8+PD-1+ and CD4+PD-1+ Cells in Peripheral Blood of Patients with Chronic Lymphocytic Leukemia Are Independent of Binet Stage and Are Significantly Higher Compared to Healthy Volunteers. Acta Haematologica. 134(4). 208–214. 15 indexed citations

11.

Tichý, M, Zuzana Kubová, Tomáš Papajík, et al.. (2014). Diffuse large B-cell lymphoma: The history, current view and new perspectives. Neoplasma. 62(5). 491–504. 8 indexed citations

12.

Papajík, Tomáš, et al.. (2013). Expression of miR-15a and miR-16-1 in patients with chronic lymphocytic leukemia. Biomedical Papers. 157(4). 284–293. 15 indexed citations

13.

Procházka, Vít, Edgar Faber, Luděk Raida, et al.. (2012). High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma. Leukemia & lymphoma. 53(7). 1306–1310. 12 indexed citations

14.

Papajík, Tomáš, А. Малан, Vladimír Koza, et al.. (2011). Determining the extent and stage of disease in patients with newly diagnosed non-Hodgkin’s lymphoma using 18F-FDG-PET/CT. Neoplasma. 58(4). 291–297. 1 indexed citations

15.

Papajík, Tomáš, Vít Procházka, Luděk Raida, et al.. (2011). Synchronous Second Primary Neoplasms Detected by Initial Staging F-18 FDG PET/CT Examination in Patients With Non-Hodgkin Lymphoma. Clinical Nuclear Medicine. 36(7). 509–512. 22 indexed citations

16.

Szotkowski, Tomáš, et al.. (2009). Precursor T-Lymphoblastic Lymphoma as a Secondary Malignancy in a Young Patient after Successful Treatment of Acute Promyelocytic Leukemia. Onkologie. 32(8-9). 513–515. 4 indexed citations

17.

Procházka, Vít, Edgar Faber, Luděk Raida, et al.. (2009). PROLONGED SURVIVAL OF PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA AFTER FIRST-LINE INTENSIVE SEQUENTIAL CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION. Biomedical Papers. 153(1). 63–66. 9 indexed citations

18.

Šauer, Pavel, et al.. (2006). SOURCES AND PATHWAYS OF SPREAD OF VANCOMYCIN-RESISTANT ENTEROCOCCI IN HEMATO-ONCOLOGICAL PATIENTS. Biomedical Papers. 150(1). 117–120. 3 indexed citations

19.

Bačovský, Jaroslav, Karel Indrák, Edgar Faber, et al.. (2003). Results of therapy and changing prognosis of multiple myeloma during the last 40 years in the region of North and Middle Moravia: group of 562 patients. The Hematology Journal. 4(5). 351–357. 1 indexed citations

20.

Jarošová, Marie, et al.. (2001). Contribution of Comparative Genomic Hybridization and Fluorescence in situ Hybridization to the Detection of Chromosomal Abnormalities in B-Cell Chronic Lymphocytic Leukemia. Oncology Research and Treatment. 24(1). 60–65. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact